~" Percutaneous epidural stimulation of the low thoracic spinal cord was carried out in 41 patients with pain from peripheral arterial disease of the lower limbs. Results are reported relating to pain, claudication distance, peripheral blood flow, and trophic lesion changes. Following a trial period of stimulation, 37 patients had stimulators permanently implanted. After a mean poststimulation follow-up period of 25 months, substantial pain relief (75% to 100%) was obtained in 29 cases; claudication distance significantly increased in 15 cases; Doppler ultrasound recordings of lower-limb distal arteries showed a tendency toward normalization of pulsewave morphology, with increase of amplitude in 12 of the 23 patients studied; a rise in skin temperature was also detected by thermography. Distal arterial blood pressure remained unchanged with stimulation. Ischemic cutaneous trophic lesions of less than 3 sq cm healed, but gangrenous conditions were not benefited. A placebo effect or the natural history of the disease can be excluded as the reason for these improvements. It is concluded that spinal cord stimulation is a valid alternative treatment for moderate peripheral arterial disorders when direct arterial surgery is not possible or has been unsuccessful.
p
ATIENTS with pain problems treated with spinal cord stimulation (SCS) commonly describe a warm sensation in the affected area during stimulation. Based on this empiric observation and prior studies showing the effect of posterior root 7 and spinal cord stimulation 8 on peripheral blood flow, SCS was used to treat ischemic pain resulting from arterial insufficiency. Early clinical reports have confirmed pain relief from SCS and mentioned an increase in skin temperature and plethysmographic and rheographic amplitudes with healing of ischemic ulcers in vasculopathy patients. 4,5't~ These experiences suggest that SCS can produce an increase in peripheral blood flow, probably through a vasodilator effect. Since then, SCS has been increasingly used for the treatment of moderate peripheral arterial disorders, although several questions remain unanswered concerning the relationship between pain relief and peripheral blood flow improvement, the duration of the amelioration, and the ideal vasculopathic candidate for the therapy.
The goal of this cooperative study was to identify and present changes in ischemic pain, claudication distance, and peripheral blood flow obtained in 41 vasculopathic patients treated with SCS. Table 1 summarizes the clinical data of the 41 patients. Peripheral arterial vasculopathy was attributed to arteriosclerosis in 28 cases, diabetic angiopathy in seven, thromboangiitis obliterans in five, and Raynaud's disease in one. The general condition of these patients was poor, due to age and associated systemic disturbances. All presented with peripheral arterial insufficiency; the duration of ischemic symptoms varied from 4 to 72 months. Before stimulation, the patients had been treated unsuccessfully with drugs and various types of surgery. Uni-or bilateral sympathectomy had also failed to resolve the problem in 23 cases. Thus, before SCS, all ischemic symptoms were stable or deteriorating. Pain was ranked as absent, occasional pain, pain at night, and pain day and night. In all patients but one, pain affected the lower extremities, mainly the distal parts, unilaterally in 27 cases and bilaterally in 14. Ischemic trophic lesions were evident in 14 cases. Case 22 presented with vasomotor phenomena in both upper limbs. Before stimulation, claudication distance (defined as the distance the patient could walk before claudication occurred) was measured on 3 consecutive days using a fixed distance or a treadmill. Fourteen patients could not walk at all due to pain or had a claudication distance of less than l0 m, and none walked more than 250 m. All patients showed an ankle/ brachial pressure ratio under 0.9.
Clinical Material and Methods
Diagnoses were angiographically confirmed. Doppler studies were used to measure peripheral blood flow changes in 23 patients by exploring the dorsalis pedis and the tibialis posterior arteries. Before stimulation, an anomaly of the pulse wave with almost flat recordings or a decrease in amplitude was present in 21 of these 23 patients. Thermography was used to measure changes in skin temperature during stimulation in 23 cases. Prior to stimulation, a focal decrease in temper- ? -= no pain; + = occasional pain; ++ = night pain; +++ = pain night and day; bl = bilateral.
ature, in some cases of 2~ was detected. Cool fields were usually in distal areas, coinciding with the most painful zones. Considering the failure of all previous therapies and the impossibility of using direct arterial surgery in these cases, SCS appeared to be a valid therapy for ischemic pain that permitted study of its beneficial effects on peripheral blood flow. Routine techniques were used to introduce percutaneous leads into the epidural space and to manipulate them to the level at which stimulation provoked tingling sensations in the painful area. The leads were generally placed at the low thoracic spinal segments. Bipolar stimulation was used in 40 cases and monopolar in one. A 2-week stimulation trial period was established. A pulse width of 0.1 to 0.2 msec, at 80 to 120 Hz, and amplitude at low paresthesia threshold were found the most effective stimulation parameters. Stimulation was given during the day in periods of 1 hour on and I hour off. When patients enjoyed significant pain relief, regardless of peripheral blood improvements, the device was implanted and stimulation delivered by an external transmitter following the same stimulation program.* * Stimulation equipment was provided by Medtronic Inc., Minneapolis, Minnesota. Table 1 summarizes the results obtained in this series of patients after a mean follow-up period of 25 months.
lschemic Pain
Overall, pain relief can be considered as fairly good. In 17 cases there was total pain remission, and in 12 cases 75% pain relief was obtained. In one case pain was alleviated 50% and in six cases less than 25%. In four cases, SCS was ineffective in reducing pain and the electrodes were removed. One patient died 3 weeks after implantation. At the last examination, 17 patients were pain-free, 13 had occasional pain and needed light analgesics, six suffered night pain requiring medical treatment, and four were referred to the Department of Vascular Surgery for more drastic therapy.
Claudication Distance
Of 33 cases tested, 15 showed a marked improvement in walking capacity (that is, a significant increase in claudication distance). Eleven patients could walk over 1000 m, and carry on a normal working and social life. Before treatment, none of these patients could walk more than 250 m without claudication. In two cases, the claudication distance increased from less than 50 and 250 m, respectively, to more than 500 m. The walking capacity was increased by 250 m in another two cases, and in 12 cases walking ability was also increased although significantly less. There was no change in eight cases.
Blood Flow Studies
Spinal cord stimulation seems not to have influenced distal arterial pressure, judging by the ankle/brachial pressure ratio.
Doppler ultrasound recordings showed an improvement of blood flow in the lower-limb distal circulation after stimulation, expressed by higher blood flow velocity, with a tendency to normalize the morphology of the pulse wave as well as to increase its amplitude. These findings appeared in 12 of the 23 cases previously studied. The changes occurred after 10 minutes of stimulation and increased throughout the stimulation period (Fig. 1) . This increment in blood flow persisted in several studies performed months later, even in the absence of simultaneous stimulation (Fig. 2) . Figure 3 illustrates the mean variations in pulse wave amplitude throughout the stimulation period as compared with baseline control measurements.
Thermography was used in 23 patients and revealed a rise in skin temperature during SCS in 13. With stimulation, warming of the affected area was observed, increasing during the stimulation period. However, the previous thermal differences between cool and warm regions persisted (Fig. 4) . Temperature improvements cm/sec. caused by SCS were sustained in long-term follow-up studies, even with the stimulation device off (Fig. 5) .
Trophic Lesions
The effects of SCS on trophic lesions were somewhat less uniform than other clinical aspects. None of the gangrenous lesions healed nor was there reduction in the area involved. Of the patients with cutaneous ulcers, five healed totally (all with lesions under 3 sq cm), three continued unchanged after 6 months (requiring amputation), and three developed gangrene that necessitated radical surgery. The latter two groups had lesions significantly larger than 3 sq cm. Of the cases without ulcers, only one (Case 16) had a poststimulation trophic lesion. The vasomotor phenomena in Case 22 disappeared.
There were three deaths during the follow-up period, of which two were due to unrelated causes and the other to sepsis because of gangrene spread. The only technical mishap was dislodgement of a lead 13 weeks after implantation, requiring replacement.
Discussion
Effective pain relief was obtained in 73% of these patients; thus, our experience suggests that pain of vascular origin can be treated by SCS, despite that fact that improvement in peripheral blood flow is not constant. Generally, however, the more significant pain relief coincided with the more impressive increases in skin or muscle blood flow. Few patients showed significant analgesia without simultaneous ultrasonographic or thermographic improvement, and in no case was there increased peripheral blood flow without pain relief. The course of the trophic lesions depended on the stage of their deterioration. No gangrenous lesions healed even with complete pain relief. Healing of cutaneous ulcerations was related to size and depth. No ulcer over 3 sq cm or affecting bone or cartilage was cured. The best overall results were obtained in patients without trophic lesions, who had vasospastic diseases or arteriosclerosis causing pain at rest.
The improvements seen in these patients did not relate to previous surgical treatment, which was unsuccessful, and considerable periods of time had passed before stimulation was attempted. No significantly different results were found in patients with prior sympathectomy. A placebo effect can be excluded because improvement was present in almost all the patients studied. The effects were long-lasting while stimulation was continued, and the previous symptoms reappeared when stimulation ceased. The natural history of this disorder with severe vascular pain at rest is to remain stable or, more frequently, to deteriorate; this pattern was not seen in our series of patients.
Our results with SCS in patients with peripheral arterial disease are similar to those of other series reported in the literature. Meglio and CionP ~ described significant pain relief in 14 of 16 patients with vasculopathy who were treated with SCS after a mean followup period of 5 months. The same authors ~3 reported plethysmographic and rheographic improvements in 12 patients with and six without vasculopathy who underwent SCS. Augustinsson, et aL, 2 obtained marked analgesia in 75% of cases with peripheral arterial disease following SCS. Tallis, et al., ~7 presented a series of I0 patients with painful arterial insufficiency treated with SCS; after a mean follow-up period of 8 months, pain relief was obtained in four patients, increase in claudication distance in six, and improvement of trophic conditions in three. Recently, Fiume 6 reported significant pain relief in 10 of 12 patients with vasculopathy after SCS; ultrasonographic and rheographic recorders showed improvement of blood flow in four cases.
Various mechanisms have been implicated in peripheral blood flow changes induced by SCS. These include autonomic nervous system activation, z,3,9,j2 local vascular control, 14'6 vasodilator peptides, prostaglandins, and prostacyclins? 5,~7 However, most of the blood flow improvements could be explained by pain relief.
To conclude, our experience shows that the ideal vasculopathy candidate for SCS is one who has pain at rest without trophic lesions or with cutaneous ulcers of less than 3 sq cm. The lack of complications and the satisfactory results in relieving ischemic pain are encouraging enough to consider SCS as a promising therapy in the management of moderate peripheral arterial disease when direct arterial surgery is not possible or has been unsuccessful. 
